Cipla Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 14,84,426 shares,. Its Average Traded Price (ATP) is ₹1413.02, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹1415.00.
Cipla has an upper circuit limit of ₹1454.80 and a lower circuit limit of ₹1370.20. The total value traded stands at ₹209.75 CR, and the delivery percentage for the day is 55.58%.
The stock is currently traded with a market lot size of 1. Cipla also offers a dividend yield of 0.92%.
Cipla Share Price Chart
Cipla Share Key Metrics
Volume
14.84 L
Market Cap
114311.97 CR
LTQ@LTP
1@1415.00
ATP
1413.02
Var Margin
12.5 %
Circuit Range
1370.2-1454.8
Delivery %
55.58 %
Value
209.75 CR
ASM/GSM
No
Market Lot
1
Cipla Resistance and Support
Pivot 1417.57
Resistance
First Resistance
1428.44
Second Resistance
1438.37
Third Resistance
1449.24
Support
First Support
1407.64
Second Support
1396.77
Third Support
1386.84
Cipla Futures & Options
1415
-3.5 (-0.25%)
Cipla Option Chain
View Price, OI, Greeks & More...
23NOV26
0.00
NaN (%)
29DEC26
0.00
NaN (%)
25JAN27
0.00
NaN (%)
CIPLA|23NOV26 CE 1410.00
6.90
-9.55 (-58.05%)
CIPLA|23NOV26 PE 1420.00
16.65
0.65 (4.06%)
Cipla Shareholding Pattern
View More- 2017-18
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Cipla Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-27 | Quarterly Results |
| 2026-07-23 | Quarterly Results |
| 2026-05-13 | Audited Results & Final Dividend |
| 2026-01-23 | Quarterly Results |
| 2025-10-30 | Quarterly Results |
| 2025-07-25 | Quarterly Results |
| 2025-05-13 | Audited Results & Final Dividend |
| 2025-01-28 | Quarterly Results |
| 2024-10-29 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-06-05 | 2026-06-05 | View More |
Cipla News
Cipla Ltd - 500087 - Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Cipla announced that the USFDA has classified the recent inspection of its InvaGen manufacturing facility in New York as No Action Indicated (NAI). The inspection was conducted between 19 and 22 October 2026.
Nov 17 2026 23:18:03
Cipla Ltd - 500087 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
The Directorate of Revenue Intelligence (DRI) conducted a search at Cipla's Vikhroli office and Bhiwandi depot on 16 Nov 2026. The search, related to customs classification and exemption of an imported pharmaceutical product, concluded the same day with no material financial impact.
Nov 16 2026 23:53:46
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cipla announced Q2 FY27 results with total revenue of Rs.7,404 cr, a 2% YoY decline, and net profit of Rs.878 cr, down 35% YoY. While the India business grew 12% YoY, North America revenue fell 19% to Rs.1,643 cr. EBITDA margin contracted to 18.7% from 25.0% in Q2 FY26.
Oct 27 2026 13:36:54
Cipla Ltd - 500087 - USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Cipla's wholly-owned subsidiary InvaGen Pharmaceuticals underwent a routine USFDA cGMP inspection at its Hauppauge, New York facility. The inspection concluded successfully with zero Form 483 observations, indicating full compliance.
Oct 23 2026 09:02:35
Cipla Management
| Name | Position |
|---|---|
| Y K Hamied | Chairman |
| Kamil Hamied | Non Independent & Non Executive Director |
Cipla Similar Stocks
Lenskart Solutions Ltd.
744.35
2.70 (0.36%)
Apollo Hospitals Enterprise Ltd.
9200.00
462.00 (5.29%)
Laurus Labs Ltd.
2294.60
-11.40 (0.49%)
Zydus Lifesciences Ltd.
1200.00
-2.90 (0.24%)
Dr. Reddy's Laboratories Ltd.
1390.20
-10.70 (0.76%)
Mankind Pharma Ltd.
2665.00
36.00 (1.37%)
Aurobindo Pharma Ltd.
1799.00
-6.70 (0.37%)
Max Healthcare Institute Ltd.
1081.00
40.35 (3.88%)
Manipal Health Enterprises Ltd.
702.20
5.75 (0.83%)
Lupin Ltd.
2014.00
15.20 (0.76%)
Cipla FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in CIPLA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC